Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation

JACC: Cardiovascular Interventions

Volumn 8, Issue 11, 2015, Pages 1457-1467

  Franchi, Francesco ^a   Rollini, Fabiana ^a   Cho, Jung Rae ^a   Bhatti, Mona ^a   DeGroat, Christopher ^a   Ferrante, Elisabetta ^a   Dunn, Elizabeth C ^a   Nanavati, Amit ^a   Carraway, Edward ^a   Suryadevara, Siva ^a   Zenni, Martin M ^a   Guzman, Luis A ^a   Bass, Theodore A ^a   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

pharmacodynamic; pharmacokinetic; platelets; ST segment elevation myocardial infarction; ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MORPHINE; TICAGRELOR; VASODILATOR STIMULATED PHOSPHOPROTEIN; ACTIN BINDING PROTEIN; ADENOSINE; ANTITHROMBOCYTIC AGENT; AR C124910XX; CELL ADHESION MOLECULE; P2RY12 PROTEIN, HUMAN; PHOSPHOPROTEIN; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG POTENTIATION; DRUG USE; FEMALE; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PERCUTANEOUS CORONARY INTERVENTION; PLASMA CONCENTRATION-TIME CURVE; PLATELET REACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BIOTRANSFORMATION; BLOOD; BLOOD CLOTTING PARAMETERS; DOSE RESPONSE; DRUG EFFECTS; INTESTINE ABSORPTION; METABOLISM; MIDDLE AGED; MYOCARDIAL INFARCTION; THROMBOCYTE;

ADENOSINE; AGED; BIOTRANSFORMATION; BLOOD PLATELETS; CELL ADHESION MOLECULES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTESTINAL ABSORPTION; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PHOSPHOPROTEINS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; TREATMENT OUTCOME;

EID: 84942121585     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2015.02.030     Document Type: Article

References (23)

1. F. Franchi, and D.J. Angiolillo Novel antiplatelet agents in acute coronary syndrome Nat Rev Cardiol 12 2015 30 47
2. R. Teng, and K. Butler Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects Eur J Clin Pharmacol 66 2010 487 496
3. P.A. Gurbel, K.P. Bliden, K. Butler, and et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study Circulation 120 2009 2577 2585
4. R.F. Storey, D.J. Angiolillo, S.B. Patil, and et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy J Am Coll Cardiol 56 2010 1456 1462
5. L. Wallentin, R.C. Becker, A. Budaj, et al. PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
6. P.G. Steg, S. James, R.A. Harrington, and et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis Circulation 122 2010 2131 2141
7. M. Valgimigli, M. Tebaldi, G. Campo, and et al. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with STsegment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial J Am Coll Cardiol Intv 5 2012 268 277
8. D. Alexopoulos, I. Xanthopoulou, V. Gkizas, and et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction Circ Cardiovasc Interv 5 2012 797 804
9. G. Parodi, R. Valenti, B. Bellandi, and et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study J Am Coll Cardiol 61 2013 1601 1606
10. D.J. Angiolillo, N. Curzen, P. Gurbel, and et al. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: results of the SWAP-2 study (Switching Anti Platelet-2) J Am Coll Cardiol 63 2014 1500 1509
11. D.J. Angiolillo, J.A. Jakubowski, J.L. Ferreiro, and et al. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease J Am Coll Cardiol 64 2014 1005 1014
12. S.E. Husted, R.F. Storey, K. Bliden, and et al. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies Clin Pharmacokinet 51 2012 397 409
13. D. Alexopoulos, I. Xanthopoulou, and J. Goudevenos Effects of P2Y12 receptor inhibition in patients with ST-segment elevation myocardial infarction Am J Cardiol 113 2014 2064 2069
14. D. Alexopoulos, V. Gkizas, S. Patsilinakos, and et al. Double versus standard loading dose of ticagrelor: onset of antiplatelet action in patients with STEMI undergoing primary PCI [letter] J Am Coll Cardiol 62 2013 940 941
15. G. Parodi, B. Bellandi, R. Valenti, and et al. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study Am Heart J 167 2014 909 914
16. W.S. Nimmo, R.C. Heading, J. Wilson, and et al. Inhibition of gastric emptying and drug absorption by narcotic analgesics Br J Clin Pharmacol 2 1975 509 513
17. E.L. Hobl, T. Stimpfl, J. Ebner, and et al. Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial J Am Coll Cardiol 63 2014 630 635
18. G. Parodi, B. Bellandi, I. Xanthopoulou, and et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention Circ Cardiovasc Interv 8 2015 e001593
19. G. Montalescot, A.W. van 't Hof, F. Lapostolle, et al. ATLANTIC Investigators Prehospital ticagrelor in ST-segment elevation myocardial infarction N Engl J Med 371 2014 1016 1027
20. F. Rollini, F. Franchi, A. Tello-Montoliu, and et al. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients J Am Coll Cardiol Intv 7 2014 426 434
21. D.J. Angiolillo, D.J. Schneider, D.L. Bhatt, and et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials J Thromb Thrombolysis 34 2012 44 55
22. P. Clemmensen, S. Wiberg, A. van't Hof, and et al. Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European Ambulance Acute Coronary Syndrome Angiography) J Am Coll Cardiol Intv 8 2015 214 220
23. G. Parodi, I. Xanthopoulou, B. Bellandi, and et al. Ticagrelor crushed tablets administration in STEMI patients: the Mashed Or Just Integral Tablets of ticagrelOr (MOJITO) study J Am Coll Cardiol 65 2015 511 512